Davis Polk, Wachtell Build Gilead's $21B Immunomedics Buy
Gilead Sciences, led by Davis Polk, will pay $21 billion for Wachtell Lipton-advised drug development firm Immunomedics, the companies said Sunday, in a deal that represents at least the fourth major...To view the full article, register now.
Already a subscriber? Click here to view full article